All Molecular Panel

The Molecular Panel ALL test is a specialised diagnostic test used to detect specific genetic and molecular abnormalities associated with Acute Lymphoblastic Leukemia (ALL), a type of blood cancer that affects the lymphoid cells in the bone marrow. ALL is one of the most common cancers in children, though it can affect adults as well. This panel analyses the blood or bone marrow sample for key chromosomal translocations, gene mutations, and fusion genes that are known to drive the development and progression of ALL. Identifying these molecular markers is essential not just for confirming the diagnosis but also for understanding how aggressive the disease is and which treatment approach is most likely to be effective. The results from this panel directly guide oncologists in personalising the treatment plan for each patient.

Who Should Get This Test Done?

The Molecular Panel ALL test is recommended for individuals who have been diagnosed with or are suspected to have Acute Lymphoblastic Leukemia. This test may be advised if a person-

●      Has been diagnosed with ALL and requires molecular subtyping

●      Shows symptoms such as unexplained fatigue, persistent fever, frequent infections, easy bruising, or unusual bleeding

●      Has abnormal white blood cell counts detected on a routine blood test

●      Has enlarged lymph nodes, spleen, or liver without a clear cause

●      Is undergoing evaluation for bone marrow failure or pancytopenia

●      Is being evaluated for eligibility for targeted therapy or bone marrow transplant

Why Consider This Test?

Acute Lymphoblastic Leukemia is not a single disease – it consists of different subtypes, each with distinct genetic changes that can influence treatment decisions. The ALL Molecular Panel helps identify these clinically significant abnormalities, allowing healthcare providers to classify the disease more accurately. The results contribute to personalized treatment planning, provide valuable prognostic information, and may also assist in monitoring the disease over time. When combined with other laboratory and clinical findings, this panel offers a comprehensive understanding of the molecular characteristics of ALL.

More Information

The ALL Molecular Panel evaluates specific gene rearrangements and chromosomal abnormalities that are frequently associated with Acute Lymphoblastic Leukemia. These molecular markers play an important role in understanding the biology of the disease and are widely used in modern hematology practice. The test is generally performed on appropriate clinical specimens and is interpreted alongside bone marrow findings, immunophenotyping, cytogenetic analysis, and other molecular investigations to provide a complete diagnostic picture.
Other Names

The Molecular Panel ALL test may also be referred to as:

●      ALL Molecular Markers Panel

●      Acute Lymphoblastic Leukemia Genetic Panel

●      ALL Cytogenetics and Molecular Panel

●      Leukemia Fusion Gene Panel

●      ALL Chromosomal Abnormality Panel

●      BCR-ABL and ALL Mutation Panel